Elissavet Nikolaou

Dr. Elissavet Nikolaou

Respiratory Clinical Research Group, Clinical Sciences, Liverpool School of Tropical Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SJSimon P. Jochems
Simon P. Jochems
KRKarin de Ruiter
Karin de Ruiter
CSCarla Solórzano
Carla Solórzano
AVAstrid Voskamp
Astrid Voskamp
EMElena Mitsi
Elena Mitsi
DFDaniela M. Ferreira
Daniela M. Ferreira
Streptococcus pneumoniae (Spn) is a common cause of respiratory infection, but also frequently colonizes the nasopharynx in the absence of disease. We used mass cytometry to study immune cells from nasal biopsy samples collected following experimental human pneumococcal challenge in order to identify immunological mechanisms of control of Spn colonization. Using 37 markers, we characterized 293 nasal immune cell clusters, of which 7 were associated with Spn colonization. B cell and CD161+CD8+ T cell clusters were significantly lower in colonized than in noncolonized subjects. By following a second cohort before and after pneumococcal challenge we observed that B cells were depleted from the nasal mucosa upon Spn colonization. This associated with an expansion of Spn polysaccharide–specific and total plasmablasts in blood. Moreover, increased responses of blood mucosa-associated invariant T (MAIT) cells against in vitro stimulation with pneumococcus prior to challenge associated with protection against establishment of Spn colonization and with increased mucosal MAIT cell populations. These results implicate MAIT cells in the protection against pneumococcal colonization and demonstrate that colonization affects mucosal and circulating B cell populations.

1 April 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EMElena Mitsi
Elena Mitsi
JRJesús Reiné
Jesús Reiné
BUBritta Christina Urban
Britta Christina Urban
CSCarla Solórzano
Carla Solórzano
ENElissavet Nikolaou
Elissavet Nikolaou
DFDaniela M. Ferreira
Daniela M. Ferreira
Background. Although recent epidemiological data suggest that pneumococci may contribute to the risk of SARS-CoV-2 disease, cases of coinfection with Streptococcus pneumoniae in patients with coronavirus disease 2019 (COVID-19) during hospitalization have been reported infrequently. This apparent contradiction may be explained by interactions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pneumococci in the upper airway, resulting in the escape of SARS-CoV-2 from protective host immune responses. Methods. Here, we investigated the relationship of these 2 respiratory pathogens in 2 distinct cohorts of health care workers with asymptomatic or mildly symptomatic SARS-CoV-2 infection identified by systematic screening and patients with moderate to severe disease who presented to the hospital. We assessed the effect of coinfection on host antibody, cellular, and inflammatory responses to the virus. Results. In both cohorts, pneumococcal colonization was associated with diminished antiviral immune responses, which primarily affected mucosal IgA levels among individuals with mild or asymptomatic infection and cellular memory responses in infected patients. Conclusion. Our findings suggest that S. pneumoniae impair host immunity to SARS-CoV-2 and raise the question of whether pneumococcal carriage also enables immune escape of other respiratory viruses and facilitates reinfection. Trial registration. ISRCTN89159899 (FASTER study) and ClinicalTrials.gov NCT03502291 (LAIV study).

22 February 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
BCBeatriz F. Carniel
Beatriz F. Carniel
FMFernando Marcon
Fernando Marcon
JRJamie Rylance
Jamie Rylance
EGEsther L. German
Esther L. German
SZSeher Zaidi
Seher Zaidi
EMElena Mitsi
Elena Mitsi
Influenza virus infections affect millions of people annually, and current available vaccines provide varying rates of protection. However, the way in which the nasal microbiota, particularly established pneumococcal colonization, shape the response to influenza vaccination is not yet fully understood. In this study, we inoculated healthy adults with live Streptococcus pneumoniae and vaccinated them 3 days later with either tetravalent-inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). Vaccine-induced immune responses were assessed in nose, blood, and lung. Nasal pneumococcal colonization had no impact upon TIV-induced antibody responses to influenza, which manifested in all compartments. However, experimentally induced pneumococcal colonization dampened LAIV-mediated mucosal antibody responses, primarily IgA in the nose and IgG in the lung. Pulmonary influenza-specific cellular responses were more apparent in the LAIV group compared with either the TIV or an unvaccinated group. These results indicate that TIV and LAIV elicit differential immunity to adults and that LAIV immunogenicity is diminished by the nasal presence of S . pneumoniae . Therefore, nasopharyngeal pneumococcal colonization may affect LAIV efficacy.

1 July 2019 in Vaccine
Verified
Journal Article
Open access
EGE.L. German
E.L. German
CSC. Solórzano
C. Solórzano
SSS. Sunny
S. Sunny
FDF. Dunne
F. Dunne
JGJenna Gritzfeld
Jenna Gritzfeld
DFD.M. Ferreira
D.M. Ferreira
Widespread use of Pneumococcal Conjugate Vaccines (PCV) has reduced vaccine-type nasopharyngeal colonisation and invasive pneumococcal disease. In a double-blind, randomised controlled trial using the Experimental Human Pneumococcal Challenge (EHPC) model, PCV-13 (Prevenar-13) conferred 78% protection against colonisation acquisition and reduced bacterial intensity (AUC) as measured by classical culture. We used a multiplex qPCR assay targeting lytA and pneumococcal serotype 6A/B cpsA genes to re-assess the colonisation status of the same volunteers. Increase in detection of low-density colonisation resulted in reduced PCV efficacy against colonisation acquisition (29%), compared to classical culture (83%). For experimentally colonised volunteers, PCV had a pronounced effect on decreasing colonisation density. These results obtained in adults suggest that the success of PCV vaccination could primarily be mediated by the control of colonisation density. Studies assessing the impact of pneumococcal vaccines should allow for density measurements in their design.

23 February 2021 in mBio
Verified
Journal Article
Open access
PDF file
ENElissavet Nikolaou
Elissavet Nikolaou
SJSimon P. Jochems
Simon P. Jochems
EMElena Mitsi
Elena Mitsi
SPSherin Pojar
Sherin Pojar
ABAnnie Blizard
Annie Blizard
DFDaniela M. Ferreira
Daniela M. Ferreira
Occurrence of lower respiratory tract infections requires prior colonization of the upper respiratory tract with a pathogen. Most bacterial infection and colonization studies have been performed in murine and in vitro models due to the current invasive sampling methodology of the upper respiratory tract, both of which poorly reflect the complexity of host-pathogen interactions in the human nose.

1 March 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HAHugh Adler
Hugh Adler
EGEsther L. German
Esther L. German
EMElena Mitsi
Elena Mitsi
ENElissavet Nikolaou
Elissavet Nikolaou
SPSherin Pojar
Sherin Pojar
JRJamie Rylance
Jamie Rylance
Rationale: Pneumococcal colonization is key to the pathogenesis of invasive disease but is also immunogenic in young adults, protecting against recolonization. Colonization is rarely detected in older adults, despite high rates of pneumococcal disease. Objectives: To establish experimental human pneumococcal colonization in healthy adults aged 50–84 years, to measure the immune response to pneumococcal challenge, and to assess the protective effect of prior colonization against autologous strain rechallenge. Methods: Sixty-four participants were inoculated with Streptococcus pneumoniae (serotype 6B; 80,000 cfu in each nostril). Colonization was determined by bacterial culture of nasal wash, and humoral immune responses were assessed by anticapsular and antiprotein IgG concentrations. Measurements and Main Results: Experimental colonization was established in 39% of participants (25/64) with no adverse events. Colonization occurred in 47% (9/19) of participants aged 50–59 compared with 21% (3/14) in those aged ≥70 years. Previous pneumococcal polysaccharide vaccination did not protect against colonization. Colonization did not confer serotype-specific immune boosting, with a geometric mean titer (95% confidence interval) of 2.7 μg/ml (1.9–3.8) before the challenge versus 3.0 (1.9–4.7) 4 weeks after colonization (P = 0.53). Furthermore, pneumococcal challenge without colonization led to a drop in specific antibody concentrations from 2.8 μg/ml (2.0–3.9) to 2.2 μg/ml (1.6–3.0) after the challenge (P = 0.006). Antiprotein antibody concentrations increased after successful colonization. Rechallenge with the same strain after a median of 8.5 months (interquartile range, 6.7–10.1) led to recolonization in 5/16 (31%). Conclusions: In older adults, experimental pneumococcal colonization is feasible and safe but demonstrates different immunological outcomes compared with younger adults in previous studies.